ArteraAI

Los Altos, California, USA · ≈160 employees · artera.ai

ArteraAI is a precision medicine company based in Los Altos, California, founded in 2021 by Andre Esteva, PhD, and Felix Feng. The company focuses on developing AI-enabled diagnostic tests to personalize cancer therapy, leveraging critical signals from histopathology images that traditional tests may overlook. ArteraAI has raised approximately $110 million in funding and has published over 40 scientific pieces related to various cancers. The flagship product, the ArteraAI Prostate Test, is recognized in the NCCN Guidelines and is reimbursed by Medicare, with around 20% of U.S. prostate cancer clinicians adopting it. The company also offers a multimodal AI platform that integrates digital biopsy images with clinical data to provide predictive insights, along with non-invasive biopsy analysis and personalized treatment decision support. ArteraAI aims to expand its capabilities to other cancers, starting with breast cancer, as part of its vision for a pan-tumor foundation model.

Hospital & Health Care

Also: hospitals & health care · b2b · diverse patient cohorts · shared decision-making · therapy benefit prediction · therapy benefit prediction in prostate cancer · ai-powered prognostics · race-diverse ai models · ai biomarker for prostate cancer · medical devices · ai in oncology · medical and diagnostic laboratories

Funding0

Every round, secondary, debt facility or acquisition involving ArteraAI that Lounge tracks, newest first.

No rounds recorded yet.

Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.

See plans →Log in

ArteraAI

Funding0

Key numbers

Also on Lounge

Similar companies